Announcement: CU Denver is Celebrating 50 Years
Whether you’re an alumnus, current student, member of the faculty and staff, donor, or neighbor, you’re a valuable part of the CU Denver community. Help us celebrate the last 50 years and a future that works for all.
Learn More
SPARK Session 17 | New approaches to drug development and target identification: use of AI
|
05:00 PM - 07:00 PM
Cost/fee: Free with RSVP Fulginiti Pavilion for Bioethics and Humanites
13080 East 19th Avenue
Aurora, CO
Cost/fee: Free with RSVP Fulginiti Pavilion for Bioethics and Humanites
13080 East 19th Avenue
Aurora, CO
https://www.nacarchitecture.com/portfolio/UCDFulginiti.html
RSVP Here
Presented by:
Sara Omlid, PhD
Partnering Executive, AtomWise
Sara Omlid, Phd is a Partnering Executive at Atomwise Inc., a biotechnology company in San Francisco that uses artificial intelligence for preclinical drug discovery and development.
Atomwise partners with companies and academic institutions on hit discovery and lead optimization projects. Dr. Omlid manages Atomwise’s successful and rapidly growing Artificial Intelligence Molecular Screen (AIMS) Awards program, which provides AI-powered virtual screening and compounds for testing to over a hundred academic researchers across the world each year.
Prior to joining Atomwise, Dr. Omlid was developing new chemistries to add to the medicinal chemist’s toolbox. She also has experience in management consulting in the biotech and life sciences industry. Dr. Omlid received her PhD and MS in physical organic chemistry as well as her bachelor’s degree in biochemistry from Saint Louis University.
Presented by:
Sara Omlid, PhD
Partnering Executive, AtomWise
Sara Omlid, Phd is a Partnering Executive at Atomwise Inc., a biotechnology company in San Francisco that uses artificial intelligence for preclinical drug discovery and development.
Atomwise partners with companies and academic institutions on hit discovery and lead optimization projects. Dr. Omlid manages Atomwise’s successful and rapidly growing Artificial Intelligence Molecular Screen (AIMS) Awards program, which provides AI-powered virtual screening and compounds for testing to over a hundred academic researchers across the world each year.
Prior to joining Atomwise, Dr. Omlid was developing new chemistries to add to the medicinal chemist’s toolbox. She also has experience in management consulting in the biotech and life sciences industry. Dr. Omlid received her PhD and MS in physical organic chemistry as well as her bachelor’s degree in biochemistry from Saint Louis University.
Add event to: